The approval makes Hanmi the first Korean company with a domestically developed GLP-1 obesity treatment, though shares fell as investors had already priced in t

The industry lobby's lawsuit challenges the administration's international reference pricing model for Medicare drugs, setting up a major legal fight over US dr

The lawsuit challenges Medicare's authority to negotiate drug prices, a central pillar of the Inflation Reduction Act.

The approval expands treatment options for HER2-positive metastatic breast cancer patients, combining a tyrosine kinase inhibitor with dual antibody therapy.

The administration's move on weight-loss drug pricing could reshape the market for GLP-1 therapies.

The biotech is discontinuing two cancer cell therapy programs, a significant setback for its allogeneic CAR-T pipeline that triggered a sharp selloff.

Upcoming changes to drug pricing rules could raise costs for millions of patients, with the October 22 deadline looming as a key date.

The decision marks a setback for Pfizer's obesity pipeline, leaving the market increasingly dominated by Eli Lilly and Novo Nordisk.

The trial start comes as Moderna awaits an FDA decision on its flu vaccine, with both programs central to its post-COVID pipeline expansion.

The pharma company is appealing a ruling on drug pricing law to the Fourth Circuit, continuing its legal fight over Medicare negotiation provisions.

Price disparities between Japan and South Korea are driving cross-border purchases of Eli Lilly's weight-loss drug, highlighting access and pricing gaps in the

Drugmakers are tapping into the consumer-driven demand for GLP-1 weight-loss drugs, a shift reshaping pharmaceutical marketing.

The FDA acceptance moves BioMarin's VOXZOGO closer to full approval for children with achondroplasia, expanding its label beyond the initial accelerated approva

The FDA acceptance moves BioMarin's VOXZOGO closer to full approval for children with achondroplasia, expanding its label beyond the initial accelerated approva

Drug developers are focusing on sustaining weight loss beyond current GLP-1 treatments, a key unmet need in the obesity market.

The designation supports development of a new treatment for sickle cell disease, which affects about 100,000 people in the US.

New tariffs on pharmaceutical imports are drawing attention to sector ETFs as investors assess the impact on drugmakers' supply chains and margins.

A leading weight-loss drug maker announced new pricing, in a market where competition and policy pressure are intensifying.